Dr Casulo
Ahmed S et al. Lisocabtagene maraleucel in R/R FL (TRANSCEND FL): Impact of prior lines of therapy, bendamustine exposure, and disease progression ≤ 24 months of initial systemic therapy. International Conference on Malignant Myeloma (ICML) 2025;Abstract 142.
Burke JM et al. MORNINGSUN: Open-label phase II trial of the efficacy and safety of subcutaneous mosunetuzumab (MOSUN SC) as frontline (1L) treatment in symptomatic patients with marginal zone lymphoma (MZL). EHA 2025;Abstract S232.
Dreyling M et al. Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial. EHA 2025;Abstract S233.
Flinn IW et al. Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study. ASCO 2025;Abstract 7014.
Heß G et al. Fixed-duration subcutaneous mosunetuzumab demonstrates clinically relevant efficacy in patients with relapsed/refractory follicular lymphoma with high-risk features: Pivotal phase II study update. EHA 2025;Abstract PS1872.
Jain P et al. Acalabrutinib in combination with rituximab is highly effective frontline treatment for older patients with mantle cell lymphoma. ICML 2025;Abstract 272.
Palomba ML et al. Lisocabtagene maraleucel (LISO-CEL) in patients (PTS) with relapsed or refractory (R/R) marginal zone lymphoma (MZL) in the phase 2 TRANSCEND FL Study. ICML 2025;Abstract 55.
Thieblemont C et al. 4-year update of phase 2 ELARA trial: Clinical outcomes of tisagenlecleucel in patients (PTS) with high-risk relapsed/refractory follicular lymphoma (R/R FL). EHA 2025;Abstract PS2150.
Trneny M et al. Tafasitamab (TAFA) plus lenalidomide (LEN) and rituximab (R) for patients with relapsed or refractory follicular lymphoma (R/R FL): Results from the phase 3 INMIND Study. EHA 2025;Abstract S230.
Vitolo U et al. Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed/refractory follicular lymphoma. EHA 2025;Abstract PF881.
Wang ML et al. minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Results from the phase 3 ECHO trial. EHA 2025;Abstract PF882.
Dr Kahl
Abramson JS et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. ASCO 2025;Abstract 7015.
Alderuccio JP et al. Initial results from LOTIS-7: A phase 1B study of loncastuximab tesirine plus glofitamab in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL). EHA 2025;Abstract PS1911.
Armand P et al. WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma. ASCO 2025;Abstract 7005.
Calabretta E et al. The benefit of POLA-R-CHP in DLBclass-defined molecular subsets of newly diagnosed DLBCL in the POLARIX trial. International Conference on Malignant Myeloma (ICML) 2025;Abstract LBA1.
Carlo-Stella C et al. Updated safety run-in results from LOTIS-5: A phase 3, randomized trial of loncastuximab tesirine with rituximab versus immunochemotherapy in patients with R/R DLBCL/HGBL. EHA 2025;Abstract PS1957.
Crombie JL et al. A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma. ICML 2025;Abstract 74.
Eyre TA et al. SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies. ASCO 2025;Abstract TPS7083.
Kerr D et al. Durable efficacy with fixed-duration epcoritamab + polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CHP) for 1L diffuse large B-cell lymphoma (EPCORE NHL-5). EHA 2025;Abstract S247.
Kim TM et al. Safety and efficacy of AZD0486, a CD19 x CD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma. ASCO 2025;Abstract 7046.
Matasar M et al. Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (POLA-R-GEMOX) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from the randomized phase III POLARGO trial. EHA 2025;Abstract S101.
Salles G et al. Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. ASH 2024;Abstract 469.
Shadman M et al. TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies. ASCO 2025;Abstract TPS7091.
Westin J et al. Mosunetuzumab plus polatuzumab vedotin is superior to R-GemOx in transplant-ineligible patients with R/R LBCL: Primary results of the phase III SUNMO trial. ICML 2025;Abstract LBA3.